- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07800676
A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Arthritis is an inflammation of one or more joints that is characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. Osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. Some patients are caused by injury or congenital abnormalities in the proteins that make up cartilage.
Once the cartilage tissue changes from smooth to rough, or into small pieces. Cartilage is gradually destroyed, and the normally smooth surface becomes irregular. Osteoarthritis usually occurs in joints that require weight load, such as the spine, knees, hips and back, and is usually preceded by some pain and Symptoms of stiffness (mostly stiffness first, then pain), but swelling is not necessarily present. However, a small number of them will cause disability, but once the bones become more fragmented, they are more likely to cause fractures. When osteoarthritis is more severe, the bones can overgrow into osteophytes, known as bone spurs. When bone spurs develop, they can be detected with X-rays, usually in the neck or waist near degenerative cartilage. Formation, these phenomena will not produce any changes in appearance.
Osteoarthritis usually does not occur in adults under the age of 40. Most patients are over the age of 60. Symptoms may be so mild that you are unaware of them until detected by X-ray. The incidence is almost higher in women than in men. three times. Degenerative arthritis is increasing among the elderly in Taiwan. It has become a very important health problem and directly affects the quality of life. Pain control can improve the quality of life.
Previous studies have shown that orally administered hyaluronic acid (HA) can bind to toll-like receptor 4 (TLR-4) on intestinal epithelial cells, thereby increasing the secretion of the anti-inflammatory cytokine IL-10 and suppressor of cytokine signaling 3 (SOCS3), while suppressing the expression of the pro-inflammatory cytokine pleiotrophin, ultimately alleviating osteoarthritis. Regarding the regulation of cartilage degradation-related factors, HA can reduce irregularities on the cartilage surface as well as the loss of cartilage tissue and chondrocytes by suppressing the mRNA expression of MMP-3, MMP-9, and MMP-13 in cartilage tissue. In terms of oxidative stress, HA may also alleviate cartilage damage by downregulating inducible nitric oxide synthase (iNOS), thereby reducing nitric oxide (NO) production, and by inhibiting cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production. To further enhance its efficacy in improving osteoarthritis, hyaluronic acid was combined with glucosamine and chondroitin. Previous studies have demonstrated that these two ingredients can improve connective tissue function and reduce cartilage matrix degradation. Therefore, the aim of this study was to investigate the effects of A+HA premium oral hyaluronic acid drink on improving knee pain.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Taipei, Taiwan
- Taipei Medical University
-
Contatto:
- YiWen Chien, PhD
- Numero di telefono: +886 2-27361661 #28363
- Email: ychien@tmu.edu.tw
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Aged 45 to 80 years.
- Knee osteoarthritis classified as Ahlbäck stage I or II, or Kellgren-Lawrence grade <3.
- A Visual Analogue Scale (VAS) pain score ≤3.
- A Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score >2 or a total WOMAC score >12.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Individuals with a history of knee joint trauma or surgery.
- A body mass index (BMI) ≥ 40 kg/m².
- Individuals with a psychiatric disorder.
- Individuals with severe cardiovascular disease, severe cerebrovascular disease, severe rheumatic disease, crystal deposition arthropathy, or cancer.
- Individuals who use a wheelchair and have a Manual Muscle Testing (MMT) grade ≤3 in the lower extremities, or who require a wheelchair due to physical discomfort.
- Use of anti-inflammatory analgesics, corticosteroids, or other medications that may affect the study outcomes within one week before the trial.
- Receipt of intra-articular corticosteroid injections, hyaluronic acid injections, platelet-rich plasma (PRP) therapy, or nerve block treatment within one month before the trial.
- Use of medications or consumption of foods that, in the judgment of a physician or dietitian, may affect the outcome measures.
- Any other condition considered by the physician to make the individual unsuitable for participation in the trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
Placebo use contents without active ingredients
|
1 drink daily
|
|
Sperimentale: A+HA premium oral hyaluronic acid drink
A+HA premium oral hyaluronic acid drink contains hyaluronic acid, glucosamine hydrochloride, and chondroitin
|
1 drink daily
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Points change of pain evaluation scale
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain.
Explain to the subjects that the pain intensity increases from left to right.
Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark.
Record the points that the subjects wrote.
|
From the start to the end of treatment at 12 weeks
|
|
Points change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points).
The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points).
The higher score meant worse knee joint function.
Record the points that the subjects got.
|
From the start to the end of treatment at 12 weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Concentration change of aspartate aminotransferase (AST)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of alanine aminotransferase (ALT)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood glucose
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of high-density lipoprotein
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of low-density lipoprotein
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of free fatty acid
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of cholesterol
Lasso di tempo: From the start to the end of the treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of the treatment at 12 weeks
|
|
Concentration change of triglyceride
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Count change of differential count (DC)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Mean corpuscular volume (MCV)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hemoglobin
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hematocrit
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Red blood cell count
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of gamma-glutamyl transferase (γ-GT)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of albumin
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood urea nitrogen (BUN)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of creatinine
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urea acid
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroid-stimulating hormone (TSH)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of triiodothyronine (T3)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroxine (T4)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of sodium (Na)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of potassium (K)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of calcium (Ca)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of magnesium (Mg)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of phosphorus (P)
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Change of urine pH value
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine protein
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine glucose
Lasso di tempo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- N202606002
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .